Global WholeHealth Partners Corp. (OTC: GWHP), a multinational supplier of over 70+ FDA Approved Diagnostic Tests, attains breakthrough on rising neurological disease. “This could simply be described as nothing short of a Medical Breakthrough in Alzheimer’s Disease Diagnostic Testing for us,” said Charles Strongo, CEO of Global WholeHealth Partners Corp. (OTC:GWHP). Global WholeHealth Partners now has the means to identify and test for Alzheimer’s disease using a Micro-Well Reader or Lateral Flow Test to measure the certain brain enzymes during the data collection process used in a positive diagnosis. This was disclosed in an 8K filed March 21, 2021 which can be found by clicking here.   “We believe this announcement couldn’t come at a better time for us as we are partnering with Nunzia Pharmaceutical and their products for Neurological disorders,” said Mr. Strongo The number of Americans living with Alzheimer’s is growing — and growing fast. More than 6 million Americans of all ages have Alzheimer’s. An estimated 6.2 million Americans age 65 and older are living with Alzheimer’s dementia in 2021. Seventy-two percent are age 75 or older. https://www.alz.org/alzheimers-dementia/facts-figures Alzheimer’s disease is currently ranked as the sixth leading cause of death in the United States, but recent estimates indicate that the disorder may rank third,   Read more…